CHULA VISTA, Calif. — If Zoe Dewaghe wants ice cream for breakfast, she gets ice cream for breakfast. There’s a different set of rules for her younger brother, Zach: He gets oatmeal instead.

That’s because five-year-old Zoe has a rare genetic disease called Sanfilippo syndrome. Her body can’t metabolize certain sugars properly, leading to progressive brain damage. She’ll gradually lose the ability to speak, to move, to recognize her surroundings. Most patients don’t live into adulthood.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I enjoyed reading this story, which highlights the challenges in rare diseases. It’s a pity that you did not report on the French biotech Lysogene, which is active in Sanfilippo gene therapy and was founded by a parent of a child with the disease: http://www.lysogene.com/about/management-team/
    Also, you explain the high price tag for these therapies well, but incompletely. The manufacturing costs for drugs for extremely rare diseases, even for conventional drugs, are staggering, because as for high-volume drugs, the system of quality, manufacturing and drug safety surveillance must be applied to them. However, these costs can only be divides over a much smaller number of units sold.

    Disclosure: I work in pharma and rare diseases. I have no relation to Lysogene.

  • Stock promoters responsible for numerous biotech wipeouts run this “company,” while ABEO temporarily trades near the highest market capitalization in its 20-year history.

  • Impactful writing and exemplary stories. The viewpoints of regulators, parents, the affected children and siblings, the pharma and biotech folks, foundations and physicians are presented vividly. Not only can these different perspectives be understood; they can be felt. Much accomplished in a few words. Well done.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy